Lipicard (TRICOR)200Mg – 100 tablet

$72.25

Each Lipicard contains 200 mg FENOFIBRATE 100 tablets per box. Used to decrease high cholesterol and triglycerides levels in the blood.

ATC Classification: C10AB05
Active Ingrediant: FENOFIBRATE
Generic Name: Lipicard
Manufacturer: USV Ltd
Strength: 200Mg
Dosage Type: Capsule
Packaging Type: Foil in Box
Contains: 100 Caps

Examples of Packages sent

Free worldwide shipping on all orders over $50

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Guaranteed Safe Checkout

Placeholder
Lipicard (TRICOR)200Mg – 100 tablet
$72.25

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Medication Safety Issues

Sound-alike/look-alike issues:

Fibricor may be confused with Tricor

TriCor may be confused with Fibricor, Tracleer

TriLipix may be confused with Trileptal, TriLyte

 

Storage/Stability

Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect Fibricor, Lipofen, Lofibra, TriCor, Triglide, and Trilipix from moisture. Protect Fibricor, Lofibra tablets, Lipofen, and Triglide from light.

Lipidil EZ, Lipidil Supra [Canadian products]: Store at 15°C to 30°C (59°F to 86°F). Protect from light and moisture.

 

Adverse Reactions

>10%: Hepatic: Increased serum transaminases (≥3 x ULN: 5% to 13%)

1% to 10%:

Cardiovascular: Pulmonary embolism (≤5%), thrombophlebitis (≤5%)

Central nervous system: Dizziness (≥3%), pain (≥3%)

Dermatologic: Skin rash (1%), urticaria (1%)

Gastrointestinal: Abdominal pain (5%), diarrhea (≥3%), dyspepsia (≥3%), constipation (2%)

Hepatic: Abnormal hepatic function tests (8%), increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (3%)

Neuromuscular & skeletal: Arthralgia (≥3%), limb pain (≥3%), myalgia (≥3%), increased creatine phosphokinase in blood specimen (3%)

Respiratory: Nasopharyngitis (≥3%), sinusitis (≥3%), upper respiratory tract infection (≥3%), rhinitis (2%)

<1%, postmarketing, and/or case reports: Acute renal failure, agranulocytosis, anaphylaxis, anemia, angioedema, asthenia, cholestatic hepatitis, chronic active hepatitis, decreased HDL cholesterol (severe), decreased hematocrit, decreased hemoglobin, decreased white blood cell count, drug reaction with eosinophilia and systemic symptoms, headache, hepatic cirrhosis, hepatitis, hepatocellular hepatitis, hypersensitivity reaction, increased serum creatinine, interstitial pulmonary disease, muscle spasm, myopathy, pancreatitis, renal failure syndrome, rhabdomyolysis, severe dermatological reaction (severe cutaneous adverse reactions [SCAR]), skin photosensitivity, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type